The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements

@article{McCreary2016TheN5,
  title={The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements},
  author={Andrew C McCreary and Mark A. Varney and Adrian Newman-Tancredi},
  journal={Neuropharmacology},
  year={2016},
  volume={105},
  pages={651-660}
}

Effects of the Serotonin 5-HT1A Receptor Biased Agonists, F13714 and F15599, on Striatal Neurotransmitter Levels Following l-DOPA Administration in Hemi-Parkinsonian Rats

The interpretation that F13714 and F15599 mediate their anti-dyskinetic effects by blunting of the peak in dopamine levels via activation of somatodendritic serotonin 5-HT1A receptors and the consequent inhibition of serotonergic neurons is supported.

Different Alterations of Agonist and Antagonist Binding to 5-HT1A Receptor in a Rat Model of Parkinson's Disease and Levodopa-Induced Dyskinesia: A microPET Study.

The data suggest that agonist and antagonist 5-HT1A receptor-binding sites are differently modified in Parkinson's disease and levodopa-induced dyskinesia and emphasize the need to characterize this state using agonist radiotracers in physiological and pathological conditions.

Serotonergic targets for the treatment of l-DOPA-induced dyskinesia

The rationale for continued investigation of several potential anti-dyskinetic strategies including 5-HT stimulation of 5- HT1A and5-HT1B receptors and blockade of 5 -HT2A receptors and SERT is discussed.

Serotonergic system modulation holds promise for L-DOPA-induced dyskinesias in hemiparkinsonian rats: A systematic review

There is promising evidence regarding the role of these agents in relieving LIDs in hemiparkinsonian rats, but further studies are needed for the enlightenment of hidden aspect of these molecules in terms of mechanisms and outcomes.

The selective 5-HT1A receptor agonist NLX-112 displays anxiolytic-like activity in mice

NLX-112 may possess anxiolytic properties which complement its known activity in models of movement disorders, and befiradol, a highly selective, potent and efficacious 5-HT1A receptor full agonist, may be associated with anxiety-like behaviours in mice.

NLX-112, a highly selective 5-HT1A receptor agonist: Effects on body temperature and plasma corticosterone levels in rats

References

SHOWING 1-10 OF 48 REFERENCES

[Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease].

Tandospirone is effective in alleviating L-DOPA-induced dyskinesia in 50% of the patients, however, at the same time 50% patients showed slight worsening of parkinsonian features.

Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.

It is shown that dyskinesia induced by chronic L-DOPA treatment in rats with 6-hydroxydopamine-induced lesions of the nigrostriatal dopamine pathway is critically dependent on the integrity and function of the serotonergic system.

Role of dopamine D3 and serotonin 5-HT1A receptors in l-DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease

An involvement of D3 receptors in the action of sarizotan on some, but not all l-DOPA-induced motor side effects is identified, in contrast to the more general involvement of 5-HT1A receptor in the anti-dyskinetic effects of sarzotan.

L-DOPA-induced dyskinesia, is striatal dopamine depletion a requisite?

  • P. Huot
  • Biology, Psychology
    Journal of the Neurological Sciences
  • 2015

l-DOPA-Induced Dyskinesia in the Intrastriatal 6-Hydroxydopamine Model of Parkinson's Disease: Relation to Motor and Cellular Parameters of Nigrostriatal Function

These results are the first to demonstrate that selective and partial DA denervation in the sensorimotor part of the striatum can confer cellular and behavioral supersensitivity to L-DOPA, and that the phenomenology of L- DOPA-induced rat AIMs can be accounted for by the topography ofDA denervation within the caudate-putamen.